The increasing incidence of diseases affecting the central nervous system 25 (CNS) demands the urgent development of efficient drugs. While many of 26 these medicines are already available, the Blood Brain Barrier and to a lesser 27 extent, the Blood Spinal Cord Barrier pose physical and biological limitations 28 to their diffusion to reach target tissues. Therefore, efforts are needed not only 29 to address drug development but specially to design suitable vehicles for 30 delivery into the CNS through systemic administration. In the context of the 31 functional and structural versatility of proteins, recent advances in their 32 biological fabrication and a better comprehension of the physiology of the 33 CNS offer a plethora of opportunities for the construction and tailoring of plain 34 nanoconjugates and of more complex nanosized vehicles able to cross these 35 barriers. We revise here how the engineering of functional proteins offer drug 36 delivery tools for specific CNS diseases and more transversally, how proteins 37 can be engineered into smart nanoparticles or 'artificial viruses' to afford 38 therapeutic requirements through alternative administration routes. 39 40 41
Introduction 45
The maintenance of the central nervous system (CNS) homeostasis is 46 essential for its normal function. The limits of the CNS tissue are establishedby the astrocytic glia limitans facing the meninges and the blood vessels, and 48 by the ependimocytes of the choroid plexus were the cerebrospinal fluid is 49 produced (Figure 1 A) . Astrocyte end-feet wrap the meningeal fibroblasts and 50 the endothelial cells (ECs) of the capillaries, leaving between them the 51 basement membrane. Brain capillaries display a large surface area (~20 m The delivery of substances across the Blood Cerebrospinal Fluid 113
Barrier (BCFB) may also be considered as an interesting option. This barrier 114
shows a morphological correlate with the BBB at the level of tight junctions 115 between the cells. These, however, are not located at the ECs capillaries that 116 are in fact fenestrated (Figure 1 C) , but on the apical surface of the epithelial 117 cells of the choroid plexus and the arachnoid fibroblasts along the blood 118 vessels, inhibiting paracellular diffusion of hydrophilic molecules across this 119 BBB permeability is linked to the dysfunction of the CNS (Rosenberg 2012) . 147
For instance, inflammation is a common feature of both chronic and acute 148 CNS injuries and it is one of the main causes of the expansion of the 149 neuropathology to adjacent CNS tissue areas. Many inflammatory mediators, 150 like tumor necrosis factor-α (TNFα), induce BBB permeability acting directly 151 on ECs (Deli et al. 1995) or indirectly by activating astrocytes to secrete other 152 proinflammatory mediators like IL-1β (Didier et al. 2003) , and in this way 153 contribute to the disease severity. In the Multiple Sclerosis model termed 154
Experimental Allergic Encephalomyelitis (EAE), the major BBB disruption 155 occurs in white matter post-capillary venules in response to inflammatory 156 stimuli (Tonra 2002) , showing that these locations can also constitute 157 important places for the entry of circulating molecules and cells into the brain. 158
After a traumatic brain injury there is a rapid extravasation of blood in the 159 central damaged areas, and intravascular coagulation and significant 160 reduction in blood flow in the pericontusional brain areas. This is followed by 161 two peaks of BBB opening at 4-6 hours and 2-3 days after the insult 162 (Chodobski et al. 2011 ). Thus, though the extent and particular moments of 163 BBB permeability varies in the different pathologies, it can be used as a 164 therapeutic time-window to deliver molecules into the CNS (Rosenberg 2012) . 165
Transient pharmacological stimulation of BBB opening for drug delivery 166 is tempting, and it can be achieved by the injection of hypertonic solutions 167 with Mannitol. However, the potential toxic effects, especially under 168 pathological conditions, are notable. Though the permeability of the BBB may 169 be spontaneously enhanced at certain time-windows post-injury, as for 170 example after Traumatic Brain or Spinal Cord Injury (Bartanusz et al. 2011) , 171 that will allow the desired drugs entering the CNS, the pharmacological 172 disruption of the BBB under pathological conditions may in contrast worsen 173 the disease progression. For instance, the pharmacological disruption of the 174 BBB enhanced the clinical severity in an EAE model (Alvarez et al. 2011) , 175
indicating that the integrity of the BBB is involved in the pathology and it also 176 modulates the recovery. In this context, the dysfunction of the BBB and BSCB 177 has been well documented in the etiology or progression of several CNS 178 pathologies (Bartanusz et al. 2011) , making the enhancement of BBB barrier 179 permeability not indicated for the delivery of drugs into the damaged CNS. Parkinson's disease (Wade and Katzman 1975 (that favors release from the BBB towards the CNS) fused to an antibody 376 against the enzyme BACE1, involved in amyloidal plaque formation. When the 377 bifunctional molecule is applied systemically, a decrease of 47 % in plaques 378 was observed in mouse models (Yu et al. 2011 ). Interestingly, the fusion of a 379 monovalent sFab of an anti-TfR antibody to an anti-Abeta antibody mediated 380 effective uptake transcytosisand TfR recycling, while the presence of two 381
Fab fragments onthe anti-Abeta antibody resulted in uptake followed by 382 traffickingto lysosomes and an associated reduction in TfR 383 levels (Niewoehner et al, 2014) . This approach exhibited enhanced in vivo 384 targeting of Abeta plaques after i.v. administration. Nerve growth factor (NGF) 385 fused to an anti-TfR antibody has also been used successfully to prevent 386 neuronal degeneration when applied intravenously in a Huntington disease 387 model (Kordower et al. 1994 ). In a similar context, a poly(mannitol-co-PEI) 388 gene transporter modified with a rabies virus glycoprotein is able to 389 ameliorates Alzheimer symptoms by transporting a therapeutic RNAi (Park, 390 2015) . Alternatively, the intranasal route to the CNS (Hanson and Frey 
Administration routes 502
The intravenous administration of functionalized nanoparticles is the 503 most used therapeutic route. However, in some cases, patient compliance is 504 not easy to achieve, and alternative administration routes need to be 505 (Figure 1 A) . Some of these treatments are still highly invasive and 511 are only addressed to high grade glioma patients. In the milder intranasal 512 delivery, the drug is being accumulated in the olfactive bulb and then diffusing 513 inside the brain. This approach has been proven to be quite effective in the 514 treatment of various disease models, acting through the olfactory pathway 
